Global Market Comments
June 12, 2019
Fiat Lux
Featured Trade:
(MONDAY, JUNE 24 MELBOURNE, AUSTRALIA STRATEGY LUNCHEON)
(AMGEN’S BIG LUNG CANCER BREAKTHROUGH),
(AMGN), (GSK), (MRTX)
Global Market Comments
June 12, 2019
Fiat Lux
Featured Trade:
(MONDAY, JUNE 24 MELBOURNE, AUSTRALIA STRATEGY LUNCHEON)
(AMGEN’S BIG LUNG CANCER BREAKTHROUGH),
(AMGN), (GSK), (MRTX)
Come join me for lunch at the Mad Hedge Fund Trader’s Global Strategy Update which I will be conducting in Melbourne, Australia on Monday, June 24, 2019 at 1:15 PM.
An excellent meal will be followed by a wide-ranging discussion and an extended question-and-answer period.
I’ll be giving you my up to date view on stocks, bonds, currencies commodities, precious metals, energy, and real estate.
I also hope to provide some insight into America’s opaque and confusing political system. And to keep you in suspense, I’ll be throwing a few surprises out there too.
Tickets are available for $232.
I’ll be arriving at 1:00 and leaving late in case anyone wants to have a one on one discussion, or just sit around and chew the fat about the financial markets.
The lunch will be held at a downtown five-star hotel, the details of which will be emailed with your purchase confirmation.
I look forward to meeting you and thank you for supporting my research.
To purchase tickets for this luncheon, please click here.
I recently heard that some of my hedge fund friends were loading up on Amgen (AMGN) and now I know why. It’s a company I know well because my UCLA biochemistry professor was its first chairman.
Amgen has accomplished a major medical breakthrough. The company has revealed that its experimental drug, AMG 510, exhibited the ability to significantly shrink the size of tumors by 50%. The results were obtained from early-stage trials performed on advanced lung cancer patients.
In a nutshell, AMG 510 could become the first-ever approved treatment that can target a mutated gene called KRAS which is one of the most common mutations involved in non-small cell lung cancer (NSCLC). The American Cancer Society identified NSCLC as the leading cause of cancer death, accounting for a stunning 85% of lung cancers.
For decades, researchers have been searching for ways to address KRAS mutations, with the sought-after solution dubbed as the "the great white whale of drug discovery." With the first proof-of-concept presented a mere six years ago, the rapid development of Amgen’s new drug has impressed researchers in the field.
Simply put, this drug will be a game changer for particular types of cancer. Subsequently, its success would mean massive profits for Amgen shareholders.
The announcement of AMG 510’s promising results saw a jump in Amgen shares of 6.1% delivering a new two-year high. While this product remains in its initial phase, the fact that this cancer drug addresses a vital unmet need in oncology makes it a prime candidate in becoming the next blockbuster drug for Amgen.
Aside from lung cancer, this drug is also aimed at providing treatment for colorectal cancer and nearly uncurable pancreatic cancer (of which Steve Jobs died). To date, AMG 510 sales are estimated to initially reach more than $1 billion a year and peak at $2 billion.
With the extremely massive market for this particular drug, it comes as no surprise that Amgen is not alone in the race.
So far, two more biopharma companies are looking to develop similar medications: GlaxoSmithKline Plc (GSK) and Mirati Therapeutics (MRTX). While the former has yet to reveal the covalent inhibitor drug it’s currently developing, reports indicate that Mirati’s work involves a drug called MRTX849. Aside from these, no other information has been released by the two companies.
While these are encouraging results vis-à-vis its oncology department, how is Amgen doing so far this year with the rest of its business?
Based on its earnings report in the first quarter of 2019, Amgen recorded $5.6 billion in total revenues. This matches the amount the company reported during the same quarter in 2018. Despite the promising projects in its pipeline, Amgen’s product sales saw a 1% dip globally.
However, its new products showed double-digit increases in the first quarter. Osteoporosis and hypercalcemia drug Prolia reported a 20% increase while cardiovascular medication Repatha also showed a 15% revenue jump during the first quarter. Even the revenues for relapsed multiple myeloma treatment Kyprolis showed a 10% rise in this period.
As for its earnings per share (EPS), Amgen is coming in at $12.53. This indicates an EPS growth of 14.8% this year, which could lead to a projected 5.25% EPS growth for 2020.
Meanwhile, Amgen’s positive outlook particularly with AMG 510 as an additional blockbuster drug in its portfolio prompted the company to adjust its earnings expectations for this year. In terms of its expected revenue, Amgen raised it from $21.8 billion to $22.9 billion range to $22 billion to $22.9 billion.
Global Market Comments
June 11, 2019
Fiat Lux
Featured Trade:
(BEYOND RATIONAL), (BYND)
(PLEASE USE MY FREE DATA BASE SEARCH)
(HOW TO AVOID PONZI SCHEMES)
Global Market Comments
June 10, 2019
Fiat Lux
Featured Trade:
(JUNE 21 AUCKLAND NEW ZEALAND STRATEGY LUNCH)
(MARKET OUTLOOK FOR THE WEEK AHEAD, OR THE GRAND PLAN)
(MSFT), (GOOGL), (AMZN), (TESLA), (TLT), ($TNX)
Come join me for lunch at the Mad Hedge Fund Trader’s Global Strategy Luncheon, which I will be conducting in Auckland, New Zealand on Friday, June 21, 2019.
An excellent meal will be followed by a wide-ranging discussion and question-and-answer period.
I’ll be giving you my up-to-date view on stocks, bonds, currencies, commodities, precious metals, and real estate.
I also hope to provide some insight into America’s opaque and confusing political system. And to keep you in suspense, I’ll be throwing a few surprises out there too. Tickets are available for $231.
I’ll be arriving early and leaving late in case anyone wants to have a one-on-one discussion, or just sit around and chew the fat about the financial markets.
The lunch will be held at a downtown boutique hotel the location of which that will be emailed with your purchase confirmation.
I look forward to meeting you and thank you for supporting my research. To purchase tickets for the luncheon, please click here.
You knew when the price of margaritas was going up that the new Mexican tariff dispute was not going to last very long, especially going into the summer. No wonder the Texas senators were so upset.
As of this writing, the tariffs have been called off two days before they were going to be implemented and a week after they were threatened. But who knows? They could be back on again at any time once the Mexicans fail to deliver on their undoubtedly impossible promises.
The Mexican standoff does, however, provide valuable lessons on how markets may perform going into the 2020 presidential election; arbitrarily create an unnecessary crisis, just as arbitrarily end it, and then collect more votes from your base.
Now let's scale this up to the trade war with China. Use fears of an impending recession to get the Fed to lower interest rates in a major way. With the economic data now falling to pieces, futures markets are currently discounting three 25 basis point rate cuts by yearend and two more in 2020. That gets the Fed funds rate down from the current 2.50% to 1.25% in a hurry.
Then what happens? A “beautiful” trade deal is signed with China, hyper-stimulating the economy in the middle of the election. What are stocks worth with a 1.25% fed funds rate? A whole lot more than they are now.
So, here is the setup for the stock market. A treacherous trading range over the next three to six months leading to lower highs and then lower lows. After that, they go ballistic next year.
I have never been a fan of conspiracy theories, and the strategy above depends on a lot of external things going incredibly right. For a start, the Chinese likely do not want to provide any assistance to the president whatsoever in getting reelected.
Still, we all need a model of how the companies, industries, the economy, and world events will transpire before we enter a single trade, and this is the best one I can come up with….today.
It’s not that interest rates are so important anymore. The biggest chunk of the stock market, large-cap tech stocks, are hugely cash flow positive, have no net debt, and actually lose money when rates fall. And rates have been so low for so long that we have all become used to free money.
The biggest impact is on the consumer who accounts for 70% of GDP. Lower credit card rates and home mortgages have an immediate and positive effect on the economy.
The May Nonfarm Payroll Report definitely cast a long shadow over the economy, coming in at only 75,000, less than half of what was expected. March and April were also revised down by an additional 75,000. The headline Unemployment Rate held steady at 3.6%.
Professional Services gained by 33,000, Construction by 4,000, and Health Care by 16,000. Retail was the biggest loser at 7,000.
If it was just one data point that was so horrible, I wouldn’t be so worried. In fact, Private jobs growth hit a nine-year low on Wednesday, with the May ADP in at only 27,000. Is this the canary in the coal mine?
The takeaway here is that the trade war is finally starting to exact its pound of flesh (I’m going to Venice after all), and that the next report could be worse. The Mexican tariffs and the antitrust assault on big tech are too recent to be reflected in the data. It makes a July Fed rate cut a slam dunk (after all, I live in Oakland).
The Justice Department has started an antitrust investigation against Google, claiming that search results favor Google-owned companies. The problem is that Google invented modern online search, with a 92.81% market share. Bing has a 2.38% market share and Yahoo has 1.89%. And while they own search, they contain only 38.2% of the online advertising market.
Microsoft (MSFT) had the same problem during the 1990s, with an antitrust suit brought by the government that lasted a decade. Before that, there was the interminable IBM antitrust suit. I thought Amazon’s (AMZN) head was supposed to be on a plate? Note: I had to Google (GOOGL) the information for this article.
The Fed Beige Book says the economy is slowing, and that is pre-Mexican tariff data. The summer slowdown is here, and GDP growth may fall under 1%. Bond, commodity, and energy markets say the recession is already here, but what do they know?
International trade is in free fall. Expect stocks to hit new 2019 lows while you’re basking on the beach. Your next GM model upgrade is trapped at the border. Sounds like a good time for me to take a trip around the world. Those camels in Egypt are looking better by the minute.
The trade war will cut global airline profits by 21%, from $35.5 billion to $28 billion, says industry trade association IATA in a forecast. More war means less first-class travel. And you wonder why airline share prices have been getting creamed (DAL), (LUV).
The bond market is now gunning for a 1.85% yield, and after that, the 2016 low of 1.33%, as a trade war escalating daily brings forward the next recession. The market has nearly given Trump his 1% cut in interest rates he has been clamoring for. It’s now up to the Fed to follow.
The New York Fed recession indicator is now at 30%, a 12-year high, and with the yield curve now inverted you have to pay attention. This one may be a predicted recession that actually happens. However, recessions usually happen when interest rates spike, not collapse, as they have done.
Thanks to the extreme volatility of the week I gave up my profits for the month of June and have to start all over again. Such is show business. We are now a mere 1.92% below our last all-time high from the previous week. Trading a narrow range with extreme volatility is about the worst kind of market to trade.
It was the antitrust news about the FANGs that really hit me, a core long of mine for the last decade. Thus, I was stopped out of positions in Amazon (AMZN) and Microsoft (MSFT). I was able to hang on to my long in Tesla (TSLA) because the spread was so deep in-the-money.
Global Trading Dispatch closed the week up 14.43% year-to-date and is down by -1.29% so far in May. My trailing one-year declined to +13.07%.
My nine and a half year profit fell back to +314.57%. The average annualized return shrank to +33.11%. With the trade war with China raging, I am now 90% in cash with Global Trading Dispatch and 100% cash in the Mad Hedge Tech Letter.
I’ll wait until the markets enjoy a brief short-covering rally before adding any short positions to hedge my longs.
The coming week will be a fairly sedentary one on the data front after last week’s jobs fireworks.
On Monday, June 10 at 12:00 PM, the May Consumer Inflation Expectations report is out.
On Tuesday, June 11, 9:00 AM EST, the May US Producer Price Index is released.
On Wednesday, June 12 at 9:30 AM, the May US Core Inflation is published.
On Thursday, June 13 at 8:30 AM, the Weekly Jobless Claims are printed.
On Friday, June 14 at 9:30 AM, May US Retail Sales are out. The Baker Hughes Rig Count follows at 2:00 PM.
As for me, I am spending the weekend packing for my 2019 Mad Hedge World Tour. I’ll be chasing down my mosquito spray for the Philippines, my ice ax and loden hat for Switzerland, my plug adapters and diarrhea treatments for India, and my hangover medicine for Australia. I know I already have all this stuff somewhere, I just have to find it.
Good luck and good trading.
John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader
"If a cluttered desk is a sign of a cluttered mind, what is an empty desk a sign of?" asked Albert Einstein.
Global Market Comments
June 7, 2019
Fiat Lux
Featured Trade:
(SUNDAY, JUNE 30 MANILA, PHILIPPINES STRATEGY LUNCHEON)
(THE CONTINUING DEATH OF RETAIL),
(AMZN), (WMT), (M), (JWN),
(TESTIMONIAL)
Global Market Comments
June 6, 2019
Fiat Lux
Featured Trade:
(WEDNESDAY, JUNE 28 PERTH, AUSTRALIA STRATEGY LUNCHEON)
(THE IRS LETTER YOU SHOULD DREAD),
(PANW), (CSCO), (FEYE),
(CYBR), (CHKP), (HACK), (SNE)
(CHINA’S COMING DEMOGRAPHIC NIGHTMARE)
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.
